Do you want to read an article? Please log in or register.
Lung ultrasound in children with cystic fibrosis - a new promising approach
Pulmonary Fibrosis
RECOMMENDED
Related content
Further Publications
Lung Ultrasound Score, Severity of Acute Lung Disease and Prolonged Mechanical Ventilation in Children
Am J Respir Crit Care Med
Oulego-Erroz I, Del Pilar De Castro-Vecino M, González-Cortés R, Alonso-Ojembarrena A, Rodríguez-Nuñez A, Palanca-Arias D, Quesada-Ortega Ú, Sanchiz-Cardenas S, Murillo-Pozo MÁ, López-González J, Sánchez-Yáñez P, Valencia-Ramos J, Fernández-de la Ballina A, Chaves-Caro N, Borrego-Domínguez R, Sánchez-Porras M, Rodríguez-Martínez M, Carballo-Martín PJ, Bermúdez-Barrezueta L, Rodríguez-Fanjul J, Vivanco-Allende A, Rodríguez-Campoy P, Vega-Puyal L, Gil-Antón J, Sánchez-Martínez I, Pérez-Quevedo O, Muñoyerro-Sesmero M, Barón-González de Suso L, Mayordomo-Colunga J
doi: 10.1164/rccm.202404-0843OC
Pulmonary Fibrosis
Impact of availability of a highly effective Cystic Fibrosis treatment (elexacaftor/tezacaftor/ivacaftor) on lung transplant waitlist and lung transplantation trends in the US
Respir Med
Merlo C, Geiger JM, Wang Z, Lyden GR, Schladt DP, McGarry L
doi: 10.1016/j.rmed.2025.108171
RECOMMENDED
Pulmonary Fibrosis
Outcomes of Single vs. Double Lung Retransplantation in Patients with Cystic Fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Heart Lung Transplant
Larson EL, Leng A, Ruck JM, Casillan AJ, Zhou AL, Ha JS, Shah PD, West NE, Merlo CA, Bush EL
doi: 10.1016/j.healun.2024.09.010
Pulmonary FibrosisFurther Publications
Elexacaftor/tezacaftor/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study
Ther Adv Respir Dis
Pepe A, Fevola C, Dolce D, Campana S, Ravenni N, Taccetti G, Salvatore D, Terlizzi V
doi: 10.1177/17534666251314706
RECOMMENDED
Pulmonary Fibrosis
Outcomes of a cross-sectional ultrasound- based study of cystic fibrosis related liver disease: A real world experience
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Kurkal K, Kuek SL, Herath D, Ong C, Harrison J, Cooney H, Poulter C, Oliver M
doi: 10.1016/j.jcf.2024.06.008
RECOMMENDED
Pulmonary Fibrosis
BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Fathima P, Pan E, Marsh J, Newall N, Meares T, McLeod C, Shanthikumar S, Jaffe A, Tai A, Ward N, Sivam S, Selvadurai H, Schultz A, Snelling T
doi: 10.1016/j.rmed.2025.108080
RECOMMENDED
Pulmonary FibrosisPneumonia
Diagnostic Accuracy of ancillary tests in Diagnosis of Cystic Fibrosis and development of Cystic Fibrosis Clinical Diagnostic Score: A multicentre prospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Dhochak N, Lodha R, Jat KR, Iqbal J, Kumar P, Goyal JP, Varkki S, Kabra SK, CF study group in alphabetical order with equal contribution
doi: 10.1016/j.rmed.2025.108087
RECOMMENDED
Further Publications
Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Pediatr Pulmonol
López Cárdenes CM, Merino Sánchez-Cañete A, Vicente Santamaría S, Gascón Galindo C, Merino Sanz N, Tabares González A, Blitz Castro E, Morales Tirado A, Garriga García M, López Rozas M, Ramos Riesgo T, Álvarez Beltrán M, Gutiérrez Martínez JR, Suárez González M, García Romero R, De la Mano Hernández A, Muñoz Codoceo MR, Martín Fernández C, Tutau Gómez C, Torcuato Rubio E, Ortiz Pérez P, Loverdos Eseverri I, García Volpe C, Salcedo Lobato E, Martín Rivada A, Castro Millan AM, Del Brio Castillo R, Sierra San Nicolás S, Murray Hurtado M, Crehuá Gaudiza E, Medina Martínez M, González Jiménez D, y grupo de trabajo de FQ y páncreas de la SEGHNP
doi: 10.1002/ppul.27272
RECOMMENDED
Pulmonary Fibrosis
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G
doi: 10.1016/S2213-2600(24)00407-7